{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:42:13Z","timestamp":1794631333466,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002673"],"award-info":[{"award-number":["82002673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ21H160032"],"award-info":[{"award-number":["LQ21H160032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sunitinib resistance can be classified into primary and secondary resistance. While accumulating research has indicated several underlying factors contributing to sunitinib resistance, the precise mechanisms in renal cell carcinoma are still unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RNA sequencing and m6A sequencing were used to screen for functional genes involved in sunitinib resistance. In vitro and in vivo experiments were carried out and patient samples and clinical information were obtained for clinical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified a tumor necrosis factor receptor-associated factor, TRAF1, that was significantly increased in sunitinib-resistant cells, resistant cell-derived xenograft (CDX-R) models and clinical patients with sunitinib resistance. Silencing TRAF1 increased sunitinib-induced apoptotic and antiangiogenic effects. Mechanistically, the upregulated level of TRAF1 in sunitinib-resistant cells was derived from increased TRAF1 RNA stability, which was caused by an increased level of N6-methyladenosine (m6A) in a METTL14-dependent manner. Moreover, in vivo adeno-associated virus 9 (AAV9) -mediated transduction of TRAF1 suppressed the sunitinib-induced apoptotic and antiangiogenic effects in the CDX models, whereas knockdown of TRAF1 effectively resensitized the sunitinib-resistant CDXs to sunitinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overexpression of TRAF1 promotes sunitinib resistance by modulating apoptotic and angiogenic pathways in a METTL14-dependent manner. Targeting TRAF1 and its pathways may be a novel pharmaceutical intervention for sunitinib-treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-022-01549-1","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T02:02:54Z","timestamp":1652148174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuanlei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangxin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-7241","authenticated-orcid":false,"given":"Gonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"1549_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research N","year":"2013","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43\u20139.","journal-title":"Nature."},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","volume":"387","author":"U Capitanio","year":"2016","unstructured":"Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894\u2013906.","journal-title":"Lancet"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2147\/OTT.S56370","volume":"7","author":"V Nerich","year":"2014","unstructured":"Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, et al. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther. 2014;7:365\u201374.","journal-title":"Onco Targets Ther."},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrurol.2014.194","volume":"11","author":"JR Bhatt","year":"2014","unstructured":"Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11:517\u201325.","journal-title":"Nat Rev Urol"},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","volume":"50","author":"AM Molina","year":"2014","unstructured":"Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, Motzer RJ. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. 2014;50:351\u20138.","journal-title":"Eur J Cancer"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2014.60.6012","volume":"33","author":"MB Atkins","year":"2015","unstructured":"Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, et al. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter Phase II Study. J Clin Oncol. 2015;33:3431\u20138.","journal-title":"J Clin Oncol"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther. 2018;17:1355\u201364.","journal-title":"Mol Cancer Ther"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3389\/fimmu.2018.02969","volume":"9","author":"MI Edilova","year":"2018","unstructured":"Edilova MI, Abdul-Sater AA, Watts TH. TRAF1 Signaling in Human Health and Disease. Front Immunol. 2018;9:2969.","journal-title":"Front Immunol"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/1873-3468.12584","volume":"591","author":"CM Kim","year":"2017","unstructured":"Kim CM, Jeong JH, Son YJ, Choi JH, Kim S, Park HH. Molecular basis for TANK recognition by TRAF1 revealed by the crystal structure of TRAF1\/TANK complex. FEBS Lett. 2017;591:810\u201321.","journal-title":"FEBS Lett"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","volume":"281","author":"CY Wang","year":"1998","unstructured":"Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680\u20133.","journal-title":"Science"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"23010","DOI":"10.1074\/jbc.M112.350538","volume":"287","author":"AJ McPherson","year":"2012","unstructured":"McPherson AJ, Snell LM, Mak TW, Watts TH. Opposing roles for TRAF1 in the alternative versus classical NF-kappaB pathway in T cells. J Biol Chem. 2012;287:23010\u20139.","journal-title":"J Biol Chem"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jid.2016.12.026","volume":"137","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Ryu JY, Min E, Oi N, Bai RH, Zykova TA, Yu DH, Moriyama K, Bode AM, Dong Z. TRAF1 Is Critical for DMBA\/Solar UVR-Induced Skin Carcinogenesis. J Investig Dermatol. 2017;137:1322\u201332.","journal-title":"J Investig Dermatol"},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1111\/crj.12789","volume":"12","author":"XX Wen","year":"2018","unstructured":"Wen XX, Wang BP, Feng T, Yuan W, Zhou J, Fang T. TNF receptor-associated factor 1 as a biomarker for assessment of non-small cell lung cancer metastasis and overall survival. Clinical Respiratory Journal. 2018;12:2197\u2013203.","journal-title":"Clinical Respiratory Journal"},{"key":"1549_CR15","doi-asserted-by":"crossref","unstructured":"Wang QS, Gao G, Zhang TS, Yao, K, Chen HY, Park MH, Yamamoto H, Wang KK, Ma WY, Malakhova M, Bode A, Dong ZG. TRAF1 is critical for regulating the BRAF\/MEK\/ERK pathway in non-small cell lung carcinogenesis. Cancer Res. 2018:3982\u201394.","DOI":"10.1158\/0008-5472.CAN-18-0429"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/sj.onc.1203768","volume":"19","author":"NM Patel","year":"2000","unstructured":"Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr, Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene. 2000;19:4159\u201369.","journal-title":"Oncogene"},{"key":"1549_CR17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/pros.20482","volume":"66","author":"R Shanmugam","year":"2006","unstructured":"Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, et al. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate. 2006;66:1498\u2013511.","journal-title":"Prostate"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2019.12.007","volume":"36","author":"Y Lee","year":"2020","unstructured":"Lee Y, Choe J, Park OH, Kim YK. Molecular Mechanisms Driving mRNA Degradation by m(6)A Modification. Trends Genet. 2020;36:177\u201388.","journal-title":"Trends Genet"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature19342","volume":"537","author":"DP Patil","year":"2016","unstructured":"Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537:369\u201373.","journal-title":"Nature"},{"key":"1549_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","volume":"28","author":"X Deng","year":"2018","unstructured":"Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507\u201317.","journal-title":"Cell Res"},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/cr.2014.151","volume":"24","author":"X Zhao","year":"2014","unstructured":"Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, Hao YJ, Ping XL, Chen YS, Wang WJ, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24:1403\u201319.","journal-title":"Cell Res"},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrg3724","volume":"15","author":"Y Fu","year":"2014","unstructured":"Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m(6)A RNA methylation. Nat Rev Genet. 2014;15:293\u2013306.","journal-title":"Nat Rev Genet"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.celrep.2017.02.059","volume":"18","author":"Q Cui","year":"2017","unstructured":"Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG, et al. m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Rep. 2017;18:2622\u201334.","journal-title":"Cell Rep"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"90-+","DOI":"10.1016\/j.cell.2017.11.031","volume":"172","author":"R Su","year":"2018","unstructured":"Su R, Dong L, Li CY, Nachtergaele S, Wunderlich M, Qing Y, Deng XL, Wang YG, Weng XC, Hu C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO\/m(6)A\/MYC\/CEBPA Signaling. Cell. 2018;172:90-+.","journal-title":"Cell."},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/onc.2017.351","volume":"37","author":"A Visvanathan","year":"2018","unstructured":"Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37:522\u201333.","journal-title":"Oncogene"},{"key":"1549_CR26","doi-asserted-by":"publisher","first-page":"e103181","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181.","journal-title":"EMBO J"},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-021-02088-1","volume":"40","author":"S Nie","year":"2021","unstructured":"Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J, Sun R, Ma X, Sun G, Meng H, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021;40:284.","journal-title":"J Exp Clin Cancer Res"},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-021-02072-9","volume":"40","author":"V Miranda-Goncalves","year":"2021","unstructured":"Miranda-Goncalves V, Lobo J, Guimaraes-Teixeira C, Barros-Silva D, Guimaraes R, Cantante M, Braga I, Mauricio J, Oing C, Honecker F, et al. The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J Exp Clin Cancer Res. 2021;40:268.","journal-title":"J Exp Clin Cancer Res"},{"key":"1549_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016;63:306\u201317.","journal-title":"Mol Cell"},{"key":"1549_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gong Z, Wang Q, Huang J, Tang C, et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534:575\u20138.","journal-title":"Nature"},{"key":"1549_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285\u201395.","journal-title":"Nat Cell Biol"},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320.","journal-title":"Nature"},{"key":"1549_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0374-y","volume":"10","author":"K Zarrabi","year":"2017","unstructured":"Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017;10:38.","journal-title":"J Hematol Oncol"},{"key":"1549_CR34","first-page":"369","volume":"2013","author":"RJ Motzer","year":"1970","unstructured":"Motzer RJ, McCann L, Deen K. Pazopanib versus sunitinib in renal cancer. N Engl J Med. 1970;2013:369.","journal-title":"N Engl J Med"},{"key":"1549_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-09-2273","volume":"16","author":"BI Rini","year":"2010","unstructured":"Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res. 2010;16:1348\u201354.","journal-title":"Clin Cancer Res"},{"key":"1549_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2014.7","volume":"1","author":"C Morais","year":"2014","unstructured":"Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2014;1:1\u201311.","journal-title":"J Kidney Cancer VHL"},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11523-016-0463-4","volume":"12","author":"I Duran","year":"2017","unstructured":"Duran I, Lambea J, Maroto P, Gonzalez-Larriba JL, Flores L, Granados-Principal S, Graupera M, Saez B, Vivancos A, Casanovas O. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Target Oncol. 2017;12:19\u201335.","journal-title":"Target Oncol"},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","volume":"17","author":"KJ Gotink","year":"2011","unstructured":"Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17:7337\u201346.","journal-title":"Clin Cancer Res"},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138.","journal-title":"Nature"},{"key":"1549_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112\u20137.","journal-title":"Nature"},{"key":"1549_CR41","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-15-0207","volume":"21","author":"GD Stewart","year":"2015","unstructured":"Stewart GD, O\u2019Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O\u2019Donnell M, Mullen P, McNeill SA, et al. Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. Clin Cancer Res. 2015;21:4212\u201323.","journal-title":"Clin Cancer Res"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287\u2013301.","journal-title":"J Control Release"},{"key":"1549_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/ni.3618","volume":"18","author":"AA Abdul-Sater","year":"2017","unstructured":"Abdul-Sater AA, Edilova MI, Clouthier DL, Mbanwi A, Kremmer E, Watts TH. The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. Nat Immunol. 2017;18:26\u201335.","journal-title":"Nat Immunol"},{"key":"1549_CR44","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254\u201370.","journal-title":"Hepatology"},{"key":"1549_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","volume":"31","author":"ZJ Li","year":"2017","unstructured":"Li ZJ, Weng HY, Su R, Weng XC, Zuo ZX, Li CY, Huang HL, Nachtergaele S, Dong L, Hu C, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase. Cancer Cell. 2017;31:127\u201341.","journal-title":"Cancer Cell"},{"key":"1549_CR46","doi-asserted-by":"publisher","first-page":"191-+","DOI":"10.1016\/j.stem.2017.11.016","volume":"22","author":"HY Weng","year":"2018","unstructured":"Weng HY, Huang HL, Wu HZ, Qin X, Zhao BXS, Dong L, Shi HL, Skibbe J, Shen C, Hu C, et al. METTL14 Inhibits Hematopoietic Stem\/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018;22:191-+.","journal-title":"Cell Stem Cell"},{"key":"1549_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep.28885","volume":"65","author":"JZ Ma","year":"2017","unstructured":"Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QG, Zhou WP, Sun SH. METTL14 Suppresses the Metastatic Potential of Hepatocellular Carcinoma by Modulating N-6-Methyladenosine- Dependent Primary MicroRNA Processing. Hepatology. 2017;65:529\u201343.","journal-title":"Hepatology"},{"key":"1549_CR48","first-page":"1068","volume":"10","author":"SP Liu","year":"2020","unstructured":"Liu SP, Li GH, Li QJ, Zhang Q, Zhuo LJ, Chen XY, Zhai BT, Sui XB, Chen K, Xie T. The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. Am J Cancer Res. 2020;10:1068\u201384.","journal-title":"Am J Cancer Res"},{"key":"1549_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.gpb.2018.04.002","volume":"16","author":"S Liao","year":"2018","unstructured":"Liao S, Sun H, Xu C. YTH Domain: A Family of N(6)-methyladenosine (m(6)A) Readers. Genomics Proteomics Bioinformatics. 2018;16:99\u2013107.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"1549_CR50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41467-020-20527-z","volume":"12","author":"B Li","year":"2021","unstructured":"Li B, Zhu L, Lu C, Wang C, Wang H, Jin H, Ma X, Cheng Z, Yu C, Wang S, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12:295.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1186\/s12943-026-02596-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01549-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:02:13Z","timestamp":1772560933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-022-01549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01549-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-026-02596-8","URL":"https:\/\/doi.org\/10.1186\/s12943-026-02596-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals were housed in the Laboratory Animal Research Center of Sir Run Run Shaw Hospital, Zhejiang University and maintained according to the guidelines of Declaration of Helsinki principles. This study was approved by the Ethics Committee of the Sir Run Run Shaw Hospital, Zhejiang university (no.2019021169), and written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}